» Articles » PMID: 26886412

Methylotroph Infections and Chronic Granulomatous Disease

Abstract

Chronic granulomatous disease (CGD) is a primary immunodeficiency caused by a defect in production of phagocyte-derived reactive oxygen species, which leads to recurrent infections with a characteristic group of pathogens not previously known to include methylotrophs. Methylotrophs are versatile environmental bacteria that can use single-carbon organic compounds as their sole source of energy; they rarely cause disease in immunocompetent persons. We have identified 12 infections with methylotrophs (5 reported here, 7 previously reported) in patients with CGD. Methylotrophs identified were Granulibacter bethesdensis (9 cases), Acidomonas methanolica (2 cases), and Methylobacterium lusitanum (1 case). Two patients in Europe died; the other 10, from North and Central America, recovered after prolonged courses of antimicrobial drug therapy and, for some, surgery. Methylotrophs are emerging as disease-causing organisms in patients with CGD. For all patients, sequencing of the 16S rRNA gene was required for correct diagnosis. Geographic origin of the methylotroph strain may affect clinical management and prognosis.

Citing Articles

An Immunodeficiency Disorder Presenting in the Neonatal Period.

Fakih H, Dbouk A Cureus. 2024; 16(4):e59374.

PMID: 38817488 PMC: 11139010. DOI: 10.7759/cureus.59374.


Unexpected cystoscopic images in a patient with Chronic Granulomatous Disease.

Kowalczyk K, Heropolitanska-Pliszka E Urol Case Rep. 2023; 48:102409.

PMID: 37187765 PMC: 10176158. DOI: 10.1016/j.eucr.2023.102409.


Pink Pigmented Facultative Methylotrophic Bacteria Isolated from Fermented Philippine Shrimp Paste.

Dela Rosa C, Lee A, Rivera W Trop Life Sci Res. 2021; 32(2):147-161.

PMID: 34367520 PMC: 8300941. DOI: 10.21315/tlsr2021.32.2.10.


, a Pathogen from Patients with Chronic Granulomatous Disease, Produces a Penta-Acylated Hypostimulatory Glycero-D-talo-oct-2-ulosonic Acid-Lipid A Glycolipid (Ko-Lipid A).

Muszynski A, Zarember K, Heiss C, Shiloach J, Berg L, Audley J Int J Mol Sci. 2021; 22(7).

PMID: 33804872 PMC: 8036547. DOI: 10.3390/ijms22073303.


Chronic Granulomatous Disease: a Comprehensive Review.

Yu H, Yang Y, Chiang B Clin Rev Allergy Immunol. 2020; 61(2):101-113.

PMID: 32524254 DOI: 10.1007/s12016-020-08800-x.


References
1.
Segal B, Leto T, Gallin J, Malech H, Holland S . Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore). 2000; 79(3):170-200. DOI: 10.1097/00005792-200005000-00004. View

2.
Greenberg D, Shoffner A, Marshall-Batty K, Arora K, Zhao M, Martin R . Serologic reactivity to the emerging pathogen Granulibacter bethesdensis. J Infect Dis. 2012; 206(6):943-51. PMC: 3501152. DOI: 10.1093/infdis/jis431. View

3.
Lopez F, Franco-Alvarez De Luna F, Delgado M, Ibarra de la Rosa I, Valdezate S, Saez Nieto J . Granulibacter bethesdensis isolated in a child patient with chronic granulomatous disease. J Infect. 2008; 57(3):275-7. DOI: 10.1016/j.jinf.2008.04.011. View

4.
Matute J, Arias A, Wright N, Wrobel I, Waterhouse C, Li X . A new genetic subgroup of chronic granulomatous disease with autosomal recessive mutations in p40 phox and selective defects in neutrophil NADPH oxidase activity. Blood. 2009; 114(15):3309-15. PMC: 2759653. DOI: 10.1182/blood-2009-07-231498. View

5.
Greenberg D, Shoffner A, Zelazny A, Fenster M, Zarember K, Stock F . Recurrent Granulibacter bethesdensis infections and chronic granulomatous disease. Emerg Infect Dis. 2010; 16(9):1341-8. PMC: 3294967. DOI: 10.3201/eid1609.091800. View